This patch can release insulin as needed
New York: An implant made from 3D printing and state-of-the-art biological materials has been developed that will continue to release insulin as needed for patients with type 1 diabetes.
The research, in its final stages, was designed by a bio-engineer at Rice University. It was designed by the World Diabetes Organization JDRF. The effort was made by two PhD students and their teacher, Omid Weiss and Jordan Miller. Jordan Miller has been developing such a patch for the past 15 years and has used a special technique called vas culture in which the blood vessels can be used and now he has brought it to 3D printing.
It involves the transformation of human stem cells from bioengineering to acetabular cells that release the right amount of insulin over time. In this way the amount of sugar (glucose) in the blood can be kept at a certain level.
Dr. Miller says that the cells in the human pancreas are arranged in a certain way and the blood vessels in them are arranged in a certain way. The two experts intended to print these impressions of nature on a chip and researched it day and night. The first target was type 1 diabetes, a security disease. In this disease the pancreas stops the production of insulin which is supplemented by vaccines.
When the new patch was tested on mice, it controlled blood sugar levels for six months. For this work, beta cells underwent genetic engineering that could immediately detect fluctuations in blood levels. But it was necessary for the transplant to be applied to a part of the body where it could detect high blood sugar and release insulin like the actual pancreas. This required that the first insulin-producing cells should not exceed 100 microns.
In view of this, the tissues were redesigned by making changes in 3D printing. Carefully place the insulin-producing cells in a hydrogel. This method of hydrogel has proven its usefulness in cell therapy by encapsulating cells. These round pearl-shaped capsules have so many tiny holes through them that insulin is released, but the security cells refrain from targeting them as strangers.
But their testing on humans is still a long way off, and a single patch is expected to be enough to release insulin for several months or a year.